On the public citation graph

A Comprehensive Analysis of FGF/FGFRSignaling Alteration in NSCLC:Implications in Prognosis and Microenvironment

0 signed · 36 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1002/cac2.12025openalex-extracted
Cancer burden of major cancers in China: A need for sustainable actions
inferredcites →https://doi.org/10.1002/dvdy.24234openalex-extracted
Wnt and FGF mediated epithelial‐mesenchymal crosstalk during lung development
inferredcites →https://doi.org/10.1002/med.21288openalex-extracted
FGF Receptors: Cancer Biology and Therapeutics
inferredcites →https://doi.org/10.1007/bf01697524openalex-extracted
Interaction of organic solvents with the green algaChlorella pyrenoidosa
inferredcites →https://doi.org/10.1007/s40265-019-01142-9openalex-extracted
Erdafitinib: First Global Approval
inferredcites →https://doi.org/10.1016/j.annonc.2022.02.001openalex-extracted
FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies
inferredcites →https://doi.org/10.1016/j.critrevonc.2020.103194openalex-extracted
Molecular testing and targeted therapy for non-small cell lung cancer: Current status and perspectives
inferredcites →https://doi.org/10.1016/j.cytogfr.2021.09.002openalex-extracted
FGF/FGFR signaling: From lung development to respiratory diseases
inferredcites →https://doi.org/10.1016/j.phrs.2019.104609openalex-extracted
Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update
inferredcites →https://doi.org/10.1016/j.phrs.2021.106037openalex-extracted
Properties of FDA-approved small molecule protein kinase inhibitors: A 2022 update
inferredcites →https://doi.org/10.1016/j.semcancer.2017.11.019openalex-extracted
Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy
inferredcites →https://doi.org/10.1016/j.xcrm.2020.100127openalex-extracted
CD103+CD8+ TRM Cells Accumulate in Tumors of Anti-PD-1-Responder Lung Cancer Patients and Are Tumor-Reactive Lymphocytes Enriched with Tc17
inferredcites →https://doi.org/10.1038/s41467-019-08887-7openalex-extracted
The Aryl hydrocarbon receptor mediates tobacco-induced PD-L1 expression and is associated with response to immunotherapy
inferredcites →https://doi.org/10.1038/s41467-022-34059-1openalex-extracted
Alveolar cell fate selection and lifelong maintenance of AT2 cells by FGF signaling
inferredcites →https://doi.org/10.1038/s41591-018-0057-zopenalex-extracted
A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade
inferredcites →https://doi.org/10.1038/s41591-021-01450-2openalex-extracted
Toward personalized treatment approaches for non-small-cell lung cancer
inferredcites →https://doi.org/10.1038/s43018-021-00292-8openalex-extracted
Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer
inferredcites →https://doi.org/10.1073/pnas.1705327114openalex-extracted
Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1–targeted therapy in lung cancer patients
inferredcites →https://doi.org/10.1080/14737140.2018.1409624openalex-extracted
Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer
inferredcites →https://doi.org/10.1093/jnci/djab116openalex-extracted
Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung Cancer
inferredcites →https://doi.org/10.1097/cm9.0000000000001474openalex-extracted
Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020
inferredcites →https://doi.org/10.1097/cm9.0000000000002108openalex-extracted
Cancer statistics in China and United States, 2022: profiles, trends, and determinants
inferredcites →https://doi.org/10.1158/1078-0432.ccr-14-3212openalex-extracted
The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing
inferredcites →https://doi.org/10.1158/1078-0432.ccr-21-2390openalex-extracted
Molecular Pathways and Mechanisms of LAG3 in Cancer Therapy
inferredcites →https://doi.org/10.1158/1535-7163.mct-16-0518openalex-extracted
Oncogenic Characterization and Pharmacologic Sensitivity of Activating Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations to the Selective FGFR Inhibitor Erdafitinib
inferredcites →https://doi.org/10.2174/0118715206259585240105051941openalex-extracted
An Expedition on Synthetic Methodology of FDA-approved Anticancer Drugs (2018-2021)
inferredcites →https://doi.org/10.2174/1871520621666210121093852openalex-extracted
Erdafitinib as a Novel and Advanced Treatment Strategy of Metastatic Urothelial Carcinoma
inferredcites →https://doi.org/10.3322/caac.21820openalex-extracted
Cancer statistics, 2024
inferredcites →https://doi.org/10.3389/fgene.2019.00170openalex-extracted
FGF Signaling in Lung Development and Disease: Human Versus Mouse
inferredcites →https://doi.org/10.3389/fimmu.2018.01904openalex-extracted
The Emerging Role of CD8+ Tissue Resident Memory T (TRM) Cells in Antitumor Immunity: A Unique Functional Contribution of the CD103 Integrin
inferredcites →https://doi.org/10.3390/cancers15051578openalex-extracted
Evolution of the Targeted Therapy Landscape for Cholangiocarcinoma: Is Cholangiocarcinoma the ‘NSCLC’ of GI Oncology?
inferredcites →https://doi.org/10.3390/cells8060614openalex-extracted
Fibroblast Growth Factor Receptors (FGFRs): Structures and Small Molecule Inhibitors
inferredcites →https://doi.org/10.3390/molecules27196733openalex-extracted
Erdafitinib Inhibits Tumorigenesis of Human Lung Adenocarcinoma A549 by Inducing S-Phase Cell-Cycle Arrest as a CDK2 Inhibitor
inferredcites →https://doi.org/10.3892/ijmm.2016.2620openalex-extracted
FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review)
inferredcites →https://doi.org/10.7150/jca.40531openalex-extracted
FGF/FGFR signaling pathway involved resistance in various cancer types
inferredcites →https://doi.org/10.7150/jca.49269openalex-extracted
Landscape of FGF/FGFR Alterations in 12,372 Chinese Cancer Patients
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.